Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System-Reference-Cited by-同舟云学术

Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System

Published:2019-07 Issue:4 Volume:20 Page:231-236
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Ezeife Doreen A.,Morganstein Brandon Josh,Lau Sally,Law Jennifer H.,Le Lisa W.,Bredle Jason,Cella David,Doherty Mark K.,Bradbury Penelope,Liu Geoffrey,Sacher Adrian,Shepherd Frances A.,Leighl Natasha B.

Funder

Cancer Care Ontario

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. The development of a financial toxicity patient-reported outcome in cancer: the COST measure;De Souza;Cancer,2014

2. Out-of-pocket spending and financial burden among medicare beneficiaries with cancer;Narang;JAMA Oncol,2017

3. Association of patient out-of-pocket costswith prescription abandonment and delay in fills of novel oral anticancer agents;Doshi;J Clin Oncol,2018

4. Financial toxicity: a potential side effect of prostate cancer treatment among Australian men;Gordon;Eur J Cancer Care (Engl),2017

5. A comparative analysis of monthly out-of-pocket costs for patients with breast cancer as compared with other common cancers in Ontario, Canada;Longo;Curr Oncol,2011

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors influencing economic toxicity and coping strategies in lung cancer patients: a scoping review;Heliyon;2024-09

2. Financial hardship experience in middle- and older-aged patients with advanced lung cancer;Supportive Care in Cancer;2024-05-22

3. Financial Toxicity and Health-Related Quality of Life Among Cancer Patients: A Correlational Study;Aquichan;2024-02-29

4. Natural sapogenins as potential inhibitors of aquaporins for targeted cancer therapy: computational insights into binding and inhibition mechanism;Journal of Biomolecular Structure and Dynamics;2024-01-04

5. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review;Lung Cancer;2024-01